Skip to main content
Equibles

Daniel Geffken

CFO

Eloxx Pharmaceuticals, Inc. (ELOX)

Chief Accounting Officer

Eloxx Pharmaceuticals, Inc. (ELOX)

Equibles does not estimate personal net worth.

Get an email with a short summary when Eloxx Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get ELOX alerts

About Daniel Geffken

Daniel Geffken is recorded as Chief Accounting Officer at Eloxx Pharmaceuticals, Inc. (ELOX) since August 17, 2021 and CFO at Eloxx Pharmaceuticals, Inc. (ELOX). The newest filing on record that lists Daniel Geffken as CFO at Eloxx Pharmaceuticals, Inc. (ELOX) is dated April 28, 2023. Earlier roles on record: CFO at CalciMedica, Inc. (CALC) until November 8, 2024. CalciMedica, Inc. reported in an 8-K filed November 8, 2024 that Daniel Geffken resigned as principal accounting officer. CalciMedica, Inc. reported in an 8-K filed November 8, 2024 that Daniel Geffken resigned as interim Chief Financial Officer. Eloxx Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Eloxx Pharmaceuticals, Inc. includes Sumit Aggarwal (CEO and Board Member), Gary D. Rakers (CFO), Neil S. Belloff (COO) and 7 others.

“On November 6, 2024, (i) Dan Geffken tendered his resignation as interim Chief Financial Officer, principal financial officer and principal accounting officer of CalciMedica, Inc., a Delaware corporation (the "Company"), effective as of one day following the filing with the Securities and Exchange Commission (the "SEC") by the Company of its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 (the "Effective Date")”
CalciMedica, Inc. Form 8-K, filed November 8, 2024 · Read the filing
“On November 6, 2024, (i) Dan Geffken tendered his resignation as interim Chief Financial Officer, principal financial officer and principal accounting officer of CalciMedica, Inc., a Delaware corporation (the "Company"), effective as of one day following the filing with the Securities and Exchange Commission (the "SEC") by the Company of its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 (the "Effective Date")”
CalciMedica, Inc. Form 8-K, filed November 8, 2024 · Read the filing

Affiliation history

Company network

Leadership on record at Eloxx Pharmaceuticals, Inc.

Recent activity